Device for Ocular Drug Delivery

  • Technology Readiness Level: 4


Ocular drug delivery is very challenging due to the complex and sensitive structure of the eye. Researchers at Purdue University have developed a minimally invasive and effective ocular drug delivery platform. This method enables long term sustained release of therapeutic ocular drugs via a tear-soluble contact lens that leaves behind biodegradable silicon nanoneedles. The tear-soluble contact lens provides an optimal curvature to fit the cornea and it is degraded in less than a minute, enabling initial short-term release of anti-inflammatory drugs and long-term release of therapeutic drugs. This technology directly benefits patients undergoing treatment for chronic diseases or injuries, including glaucoma, cataract, and graft rejection.


  • Minimally invasive
  • Long term sustained release
  • Initial burst release of anti-inflammatory
  • Long-term release of therapeutic drugs
  • Demonstrated biosafety and efficacy in lab testing

Potential Applications

  • Ocular drug delivery
  • Treatments for glaucoma, cataract, and graft rejection

Contact Information

Name: Patrick W Finnerty


Phone: 765-269-4080